Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Accenture
Johnson and Johnson
Queensland Health
Merck
Dow
Cipla
AstraZeneca
Deloitte

Generated: December 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EXEMESTANE

« Back to Dashboard

Clinical Trials for Exemestane

Trial ID Title Status Sponsor Phase Summary
NCT00002777 Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 3 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight cancer by blocking the uptake of estrogen. PURPOSE: Randomized phase II/III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women who have locally recurrent or metastatic breast cancer.
NCT00003418 Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer Unknown status European Organisation for Research and Treatment of Cancer - EORTC Phase 3 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not yet known whether exemestane is more effective than tamoxifen in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women with primary breast cancer who have already received 2-3 years of tamoxifen following surgery.
NCT00003418 Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer Unknown status UNICANCER Phase 3 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not yet known whether exemestane is more effective than tamoxifen in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women with primary breast cancer who have already received 2-3 years of tamoxifen following surgery.
NCT00003418 Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer Unknown status International Collaborative Cancer Group Phase 3 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not yet known whether exemestane is more effective than tamoxifen in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women with primary breast cancer who have already received 2-3 years of tamoxifen following surgery.
NCT00010010 Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane plus goserelin may fight breast cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of exemestane and goserelin in treating premenopausal women who have metastatic breast cancer that has not responded to previous tamoxifen.
NCT00010010 Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer Completed New York University School of Medicine Phase 2 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane plus goserelin may fight breast cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of exemestane and goserelin in treating premenopausal women who have metastatic breast cancer that has not responded to previous tamoxifen.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Exemestane

Condition Name

Condition Name for Exemestane
Intervention Trials
Breast Cancer 84
Breast Neoplasms 22
Metastatic Breast Cancer 20
HER2/Neu Negative 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Exemestane
Intervention Trials
Breast Neoplasms 167
Neoplasms 8
Breast Neoplasms, Male 5
Carcinoma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Exemestane

Trials by Country

Trials by Country for Exemestane
Location Trials
United States 787
Canada 93
Japan 60
Italy 60
United Kingdom 59
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Exemestane
Location Trials
California 34
Florida 33
Texas 33
New York 31
Washington 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Exemestane

Clinical Trial Phase

Clinical Trial Phase for Exemestane
Clinical Trial Phase Trials
Phase 4 9
Phase 3 45
Phase 2/Phase 3 1
[disabled in preview] 115
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Exemestane
Clinical Trial Phase Trials
Completed 54
Recruiting 50
Active, not recruiting 33
[disabled in preview] 43
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Exemestane

Sponsor Name

Sponsor Name for Exemestane
Sponsor Trials
National Cancer Institute (NCI) 31
Pfizer 29
Novartis Pharmaceuticals 17
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Exemestane
Sponsor Trials
Other 168
Industry 107
NIH 34
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
QuintilesIMS
Julphar
Medtronic
Cantor Fitzgerald
Moodys
McKesson
Federal Trade Commission
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.